Marucci MA, Lechner DW, Tafuto BA. Safety outcomes of low versus high dose imatinib mesylate in patients with advanced, metastatic, or nonresectable gastrointestinal stromal tumors: A systematic review. GIT. 2024;2(1). doi:10.54844/git.2023.482